Sidley acted as international counsel to lead managers Kotak Mahindra Capital Company Limited, ICICI Securities Limited, and J.P. Morgan India Private Limited in connection with the INR8.4 billion (approximately US$100 million) initial public offering (IPO) of India’s Blue Jet Healthcare Limited (Blue Jet).
Blue Jet is a specialty pharmaceutical and healthcare ingredients and intermediates company offering niche products targeted toward innovator pharmaceutical companies and multinational generic pharmaceutical companies.
The Sidley team was led by partner Manoj Bhargava and comprised counsel Shashwat Tewary and associate Edward Lee (all in Singapore) as well as partners Carla G. Teodoro, Nicholas R. Brown, and Robert M. Kreitman (all in New York) and managing associate Christian D. Barraza (Miami).
Sidley has had an active year advising India’s life sciences companies on their IPOs, including recently the US$185 million IPO of Concord Biotech and the US$530 million IPO of Mankind Pharma, India’s largest IPO in 2023.
Sidley is one of the most experienced international law firms executing capital markets transactions in India and other Asian markets. The India Business Law Journal has ranked Sidley a “Top Foreign Law Firm” for six consecutive years for its work in India. Sidley is also ranked as the leading legal adviser globally for India equity offerings in 2022 for manager counsel and by overall deal count in Bloomberg Global Legal Adviser League Tables FY 2022. Sidley was credited for advising on 12 India equity offerings in 2022, more than any other law firm.
